Compare Cytokinetics Inc (CYTK) vs Comfort Systems USA Inc (FIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Comfort Systems USA Inc — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while Comfort Systems USA Inc trades at $1,731.99 (market cap $61.29B). The key difference: Comfort Systems USA Inc is far larger — about 7.2× Cytokinetics Inc's market cap, and Comfort Systems USA Inc pays a 0.21% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Comfort Systems USA Inc for 41 Days on average.
| CYTK | FIX | |
|---|---|---|
Market Cap | $8.50B | $61.29B |
Volume | 2,395,556 | 365,637 |
Sector | Health | Industrials |
52-Week High | $87.26 | $2.07K |
52-Week Low | $54.76 | $790.72 |
Typical Hold Time | 19 Days | 41 Days |
Enterprise Value | $8.60B | $59.76B |
Dividend Yield | — | 0.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
Comfort Systems USA (FIX) trades at $1,741.36, down 4.21% today but maintains strong technical momentum with bullish moving averages. The company demonstrates robust fundamentals with revenue growth from $9.1B in 2025 to $11.2B projected for 2026, supported by consistent earnings beats and a 55.29% ROE. Recent acquisition of Hunt Electric adds $250M in annual revenue, positioning FIX to capitalize on data center and infrastructure demand.
Outlook remains positive with analyst consensus at Buy (55.56%) and $2,080 price target representing 19% upside. Key risks include execution of growing project backlog and sensitivity to construction cycle fluctuations. The stock's premium valuation (P/E 42.86) requires sustained high growth to justify current levels amid competitive market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Comfort Systems USA Inc
Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →
